Dyslipidemia / cholesterol ⭐
dyslipidemia · society: ACC/AHA · high-yield
Summary
The 2026 ACC/AHA multisociety guideline replaces the 2018 cholesterol guideline and broadens scope to dyslipidemias including LDL-C, triglycerides, and Lp(a). Major changes: adoption of PREVENT-ASCVD equations (replacing Pooled Cohort Equations) with new lower risk thresholds; reintroduction of explicit LDL-C and non-HDL-C treatment goals stratified by risk; universal one-time Lp(a) measurement; expanded role for apoB, CAC scoring (including incidental CAC on noncardiac CT), and combination nonstatin therapy (ezetimibe, PCSK9 mAb, bempedoic acid, inclisiran, olezarsen for FCS).
Current guideline: 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia · 
download Anki sub-deck